The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment

Basit Öğe Kaydı
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authoridSayin, Sezin/0000-0001-7892-5992
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.contributor.authorGokyer, Ali
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorKostek, Osman
dc.contributor.authorSaying, Sezin
dc.contributor.authorCan, Nuray
dc.contributor.authorHacioglu, Bekir
dc.contributor.authorErdogan, Bulent
dc.date.accessioned2024-06-12T11:02:25Z
dc.date.available2024-06-12T11:02:25Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: This study aimed to reveal the relationship between the level of galectin-3 expression and the depth of response to neoadjuvant therapy in bladder tumor tissue with muscle invasion revealed by transurethral biopsy. Methods: The percentage of galectin-3 staining in transurethral biopsy tissue with muscle invasion was determined by immunohistochemistry. The patients were divided into two groups: the down-staging (+) group consisting of patients with pathological complete response or non-invasive bladder cancer, and the down-staging (-) group consisting of patients with stage 2 and above. Results: There were 11 patients in the down-staging (+) group and 12 patients in the down-staging (-) group. There was no significant difference between the two groups in terms of median age, gender, smoking, clinical stage at the time of diagnosis, distribution of carboplatin or cisplatin used as a platinum agent. Galectin-3 was positive in 2 patients (18.2%) in the group where down-staging was achieved with neoadjuvant therapy, while it was positive in 9 patients (75%) in the other group (p = 0.01). The median follow-up period of the patients was 31.6 months (95% CI 25.1-39.3). Overall survival was 43.4 months in the down-staging (+) group (95% CI 25.1-61.6) and 31.6 months in the down staging (-) group (95% CI 12.7-50.6). Although there was a numerical difference, it did not reach statistical significance (p=0.37). Conclusion: The rate of down-staging after platinum-based neoadjuvant chemotherapy is significantly higher in patients with low galectin-3 staining in transurethral bladder biopsy tissue.en_US
dc.description.sponsorshipTurkish Society of Medical Oncologyen_US
dc.description.sponsorshipThis work was financially supported by the Turkish Society of Medical Oncology. The funders had no role in the study design, data collection, and analysis, decision to publish, or in the preparation of the manuscript.en_US
dc.identifier.endpage1039en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue3en_US
dc.identifier.pmid34268970en_US
dc.identifier.scopus2-s2.0-85109712399en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1034en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21279
dc.identifier.volume26en_US
dc.identifier.wosWOS:000668891800018en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGalectin-3en_US
dc.subjectBladder Canceren_US
dc.subjectNeoadjuvant Chemotherapyen_US
dc.subjectPlatinum Resistanceen_US
dc.subjectChemotherapyen_US
dc.subjectCisplatinen_US
dc.subjectMethotrexateen_US
dc.subjectVinblastineen_US
dc.subjectExpressionen_US
dc.titleThe relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatmenten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu